Cover Image

Conference on challenges in sarcoma (CCS) 2024: expert opinions on non-evidence-based management aspects

Background - Soft tissue sarcomas (STS) and other mesenchymal tumours belong to rare, heterogeneous neoplasms with over 150 subtypes that pose significant challenges in diagnosis and clinical decision making. While guidelines address evidence-based diagnostic and therapeutic procedures, clinical sit...

Full description

Saved in:
Bibliographic Details
Main Authors: Hofer, Silvia (Author) , Pauli, Chantal (Author) , Bode, Beata (Author) , Bonvalot, Sylvie (Author) , Fotopoulou, Christina (Author) , Gelderblom, Hans (Author) , Haas, Rick L (Author) , Hardes, Jendrik (Author) , Hohenberger, Peter (Author) , Jakob, Jens (Author) , Kunz, Wolfgang G. (Author) , Leithner, Andreas (Author) , Liegl-Atzwanger, Bernadette (Author) , Lindner, Lars (Author) , Miah, Aisha (Author) , Reichardt, Peter (Author) , Rutkowski, Piotr (Author) , Schaarschmidt, Benedikt M. (Author) , Scheinemann, Katrin (Author) , Szkandera, Joanna (Author) , Wardelmann, Eva (Author) , Andreou, Dimosthenis (Author) , Rothermundt, Christian (Author)
Format: Article (Journal)
Language:English
Published: 2 May 2025
In: European journal of cancer
Year: 2025, Volume: 220, Pages: 1-22
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115368
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2025.115368
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804925001492
Get full text
Author Notes:Silvia Hofer, Chantal Pauli, Beata Bode, Sylvie Bonvalot, Christina Fotopoulou, Hans Gelderblom, Rick L. Haas, Jendrik Hardes, Peter Hohenberger, Jens Jakob, Wolfgang G. Kunz, Andreas Leithner, Bernadette Liegl-Atzwanger, Lars Lindner, Aisha Miah, Peter Reichardt, Piotr Rutkowski, Benedikt M. Schaarschmidt, Katrin Scheinemann, Joanna Szkandera, Eva Wardelmann, Dimosthenis Andreou, Christian Rothermundt, on behalf of the CCS2024 panellists
Description
Summary:Background - Soft tissue sarcomas (STS) and other mesenchymal tumours belong to rare, heterogeneous neoplasms with over 150 subtypes that pose significant challenges in diagnosis and clinical decision making. While guidelines address evidence-based diagnostic and therapeutic procedures, clinical situations and scenarios without evidence remain controversial in daily practice. The 2024 Conference on Challenges in Sarcoma (CCS2024) aimed to narrow these gaps with the support of an international and multidisciplinary panel of sarcoma experts. - Methods - A Delphi process identified 200 controversial questions across eight prioritised clinical scenarios, including tenosynovial giant cell tumour, synovial sarcoma of the extremities, retroperitoneal sarcomas, angiosarcoma, phyllodes tumour, malignant peripheral nerve sheath tumour, uterine leiomyosarcoma, and atypical lipomatous tumour. - Results - Sixty-four experts discussed 141 controversies during the conference and reached strong consensus (> 90%) on 24 and consensus (> 75%) on 45 key diagnostic and therapeutic issues, while unresolved controversies emphasized the need for further research. - Conclusions - CCS2024 provides a framework for clinical decision making and underscores the importance of consensus-driven approaches in the treatment of rare and complex malignancies.
Item Description:Online verfügbar: 17. März 2025, Artikelversion: 4. April 2025
Gesehen am 04.06.2025
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115368

Similar Items